bioRxivPathologyPreprint
Osteoprotegerin is elevated in pulmonary fibrosis and associates with IPF progression
H. Habibie, K. Putri, C. E. Boorsma, D. Brass, P. Heukels, M. Wijsenbeek-Lourens, M. Kool, M. van der Berge, T. Borghuis, C. A. Brandsma, T. Gan, P. Olinga, W. Timens, N. Kahn, M. Kreuter, J. Burgess, B. N. Melgert
Abstract
Osteoprotegerin (OPG), a decoy receptor for receptor activator of NF-kB ligand (RANKL), is used as a biomarker for assessing severity of liver fibrosis. However, its expression and role in pulmonary fibrosis are unknown. We hypothesized that OPG also has a role in pulmonary fibrosis. Human and mouse control and fibrotic lung tissue were used to examine OPG expression, and mouse precision-cut lung slices to study OPG regulation in pulmonary fibrosis. Serum from idiopathic pulmonary fibrosis (IPF) patients and controls was analysed to investigate whether OPG levels correlate with disease status as measured by lung function. OPG-protein levels were significantly higher in mouse and human fibrotic lung tissue compared to control. OPG-mRNA and protein production were induced in mouse precision-cut-lung slices upon TGF{beta} stimulation and could be inhibited with galunisertib, a TGF{beta} receptor kinase inhibitor. OPG-protein levels in fibrotic mouse lung tissue correlated with degree of fibrosis. Isolated lung fibroblasts from IPF patients had higher OPG-protein levels than control fibroblasts. Serum OPG levels in IPF patients, at first presentation, negatively correlated with diffusing capacity to carbon monoxide. Finally, serum OPG levels higher than 1234 pg/ml at first presentation were associated with progression of disease in IPF patients. In conclusion, OPG is produced in lung tissue, associates with fibrosis, and may be a potential prognostic biomarker for IPF disease progression. Validation in a larger cohort is warranted to further explore the role of OPG in pulmonary fibrosis and its potential for assessing the prognosis of fibrotic lung disease in individual patients. Take home messageOsteoprotegerin is present in fibrotic lung tissue and high serum levels correlate with low lung function and IPF disease progression in this small study, indicating osteoprotegerin may have value as a biomarker to predict IPF progression
- organism: human
- organism: mouse
- assay: proteomics
- research focus: differential expression
- research focus: cell type annotation
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Interaction of osteoprotegerin with fibulin-1 is essential for extracellular matrix deposition in fibrotic lung tissue
Yanzhe Liu, Habibie Habibie, … Janette Kay Burgess·bioRxiv·Dec 5, 2024
- Contrasting responses of control and fibrotic lung fibroblasts to fibrotic stimuli: the role of osteoprotegerin in extracellular matrix remodeling
Yanzhe Liu, Mehmet Nizamoglu, … Janette Kay Burgess·bioRxiv·Feb 20, 2025
- Osteoprotegerin expression in liver is induced by IL-13 through TGF-β
A. Adhyatmika, K. S. Putri, … B. N. Melgert·bioRxiv·Dec 11, 2020
- The Role of the Ovarian Cancer G -Coupled Receptor (OGR1) in Idiopathic Pulmonary Fibrosis
D. J. Nagel, R. Clough, … M. Kottmann·bioRxiv·Nov 20, 2019
- Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis
L. Tanner, A. B. Single, … A. Egesten·bioRxiv·Feb 27, 2021
- Targeting the Oxysterol Receptor GPR183 to Mitigate Fibrogenesis in Idiopathic Pulmonary Fibrosis
Minh Dao Ngo, Cheng Xiang Foo, … Katharina Ronacher·bioRxiv·Aug 18, 2026